Core Insights - The company reported a revenue of 10.3 billion yuan and a net profit of 1.262 billion yuan for the fiscal year 2024, with a proposed cash dividend of 0.80 yuan per 10 shares [1] - Despite fluctuations in revenue due to domestic equipment update policies, the company achieved significant market performance through innovation and overseas expansion [1][2] - The company's market share for high-end products increased by nearly 5 percentage points, ranking first in the new market share for imaging products in China [3] Financial Performance - For Q1 2025, the company reported a revenue of 2.478 billion yuan and a net profit of 370 million yuan, showing a year-on-year growth of 5.42% and 1.87% respectively [2] - The service revenue for 2024 reached 1.356 billion yuan, a year-on-year increase of 26.80%, contributing 13.16% to total revenue, marking a historical peak [16] Market Position - The company achieved a 22% share of total revenue from overseas business, with a year-on-year growth of over 35% [1][12] - The company’s products are now present in over 85 countries and regions, with more than 14,800 medical and research institutions utilizing its equipment [12] Product Innovation - The company launched several innovative products, including the world's first dual-source wide-body CT and advanced MRI systems, enhancing imaging capabilities significantly [4][5] - The company has developed a vertical innovation system covering core components and systems, achieving a leading position in self-research and development of key technologies [9][10] Strategic Expansion - The company is expanding its presence in North America and Europe, with significant installations in top medical institutions and the establishment of a European headquarters [13][14] - The company is also making strides in emerging markets, with notable growth in Latin America and Africa, and has signed strategic partnerships to enhance its global reach [15] Industry Trends - The regulatory environment is becoming more supportive of high-end medical device innovation, particularly in AI-enabled medical devices, which are projected to grow significantly in the coming years [17] - The company is positioned to leverage its strong innovation capabilities and global strategy to redefine its market presence from "Made in China" to "Intelligent Manufacturing Globally" [17]